These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27054578)

  • 21. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.
    Luszczak S; Simpson BS; Stopka-Farooqui U; Sathyadevan VK; Echeverria LMC; Kumar C; Costa H; Haider A; Freeman A; Jameson C; Ratynska M; Ben-Salha I; Sridhar A; Shaw G; Kelly JD; Pye H; Gately KA; Whitaker HC; Heavey S
    Sci Rep; 2020 Sep; 10(1):14380. PubMed ID: 32873828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Next-generation sequencing identifies a novel ELAVL1-TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208.
    Tron AE; Keeton EK; Ye M; Casas-Selves M; Chen H; Dillman KS; Gale RE; Stengel C; Zinda M; Linch DC; Lai Z; Khwaja A; Huszar D
    Leuk Lymphoma; 2016 Dec; 57(12):2927-2929. PubMed ID: 27189703
    [No Abstract]   [Full Text] [Related]  

  • 23. Anti‑survival and pro‑apoptotic effects of meridianin C derivatives on MV4‑11 human acute myeloid leukemia cells.
    Cho H; Yadav AK; Do Y; Heo M; Bishop-Bailey D; Lee J; Jang BC
    Int J Oncol; 2020 Jan; 56(1):368-378. PubMed ID: 31789392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.
    Brunen D; de Vries RC; Lieftink C; Beijersbergen RL; Bernards R
    Mol Cancer Ther; 2018 Apr; 17(4):849-857. PubMed ID: 29440296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.
    Cervantes-Gomez F; Stellrecht CM; Ayres ML; Keating MJ; Wierda WG; Gandhi V
    Oncotarget; 2019 Apr; 10(29):2793-2809. PubMed ID: 31073371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell-Specific Computational Modeling of the PIM Pathway in Acute Myeloid Leukemia.
    Silverbush D; Grosskurth S; Wang D; Powell F; Gottgens B; Dry J; Fisher J
    Cancer Res; 2017 Feb; 77(4):827-838. PubMed ID: 27965317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin receptor substrate 1 is a substrate of the Pim protein kinases.
    Song JH; Padi SK; Luevano LA; Minden MD; DeAngelo DJ; Hardiman G; Ball LE; Warfel NA; Kraft AS
    Oncotarget; 2016 Apr; 7(15):20152-65. PubMed ID: 26956053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PIM kinase inhibitor AZD1208 in conjunction with Th1 cytokines potentiate death of breast cancer cellsin vitrowhile also maximizing suppression of tumor growthin vivo when combined with immunotherapy.
    Anwar A; Lepore C; Czerniecki BJ; Koski GK; Showalter LE
    Cell Immunol; 2024; 397-398():104805. PubMed ID: 38244265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
    Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
    Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
    Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
    Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
    Han L; Qiu P; Zeng Z; Jorgensen JL; Mak DH; Burks JK; Schober W; McQueen TJ; Cortes J; Tanner SD; Roboz GJ; Kantarjian HM; Kornblau SM; Guzman ML; Andreeff M; Konopleva M
    Cytometry A; 2015 Apr; 87(4):346-56. PubMed ID: 25598437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.
    Scarpa M; Singh P; Bailey CM; Lee JK; Kapoor S; Lapidus RG; Niyongere S; Sangodkar J; Wang Y; Perrotti D; Narla G; Baer MR
    Mol Cancer Ther; 2021 Apr; 20(4):676-690. PubMed ID: 33568357
    [No Abstract]   [Full Text] [Related]  

  • 33. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.
    Warfel NA; Sainz AG; Song JH; Kraft AS
    Mol Cancer Ther; 2016 Jul; 15(7):1637-47. PubMed ID: 27196781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
    Lindblad O; Cordero E; Puissant A; Macaulay L; Ramos A; Kabir NN; Sun J; Vallon-Christersson J; Haraldsson K; Hemann MT; Borg Å; Levander F; Stegmaier K; Pietras K; Rönnstrand L; Kazi JU
    Oncogene; 2016 Sep; 35(39):5119-31. PubMed ID: 26999641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rational Design of a Potent Pan-Pim Kinases Inhibitor with a Rhodanine-Benzoimidazole Structure.
    Sawaguchi Y; Yamazaki R; Nishiyama Y; Sasai T; Mae M; Abe A; Yaegashi T; Nishiyama H; Matsuzaki T
    Anticancer Res; 2017 Aug; 37(8):4051-4057. PubMed ID: 28739687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling.
    Cen B; Xiong Y; Song JH; Mahajan S; DuPont R; McEachern K; DeAngelo DJ; Cortes JE; Minden MD; Ebens A; Mims A; LaRue AC; Kraft AS
    Mol Cell Biol; 2014 Jul; 34(13):2517-32. PubMed ID: 24777602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNA-Seq analysis reveals that spring viraemia of carp virus induces a broad spectrum of PIM kinases in zebrafish kidney that promote viral entry.
    Pereiro P; Álvarez-Rodríguez M; Valenzuela-Muñoz V; Gallardo-Escárate C; Figueras A; Novoa B
    Fish Shellfish Immunol; 2020 Apr; 99():86-98. PubMed ID: 32004617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells.
    Chen W; Drakos E; Grammatikakis I; Schlette EJ; Li J; Leventaki V; Staikou-Drakopoulou E; Patsouris E; Panayiotidis P; Medeiros LJ; Rassidakis GZ
    Mol Cancer; 2010 Nov; 9():292. PubMed ID: 21067588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway.
    Okada K; Nogami A; Ishida S; Akiyama H; Chen C; Umezawa Y; Miura O
    Oncotarget; 2018 Feb; 9(10):8870-8886. PubMed ID: 29507660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.